Aveanna Healthcare (NASDAQ:AVAH) Price Target Raised to $16.00

Aveanna Healthcare (NASDAQ:AVAH) had its price objective increased by Royal Bank Of Canada from $10.00 to $16.00 in a report published on Monday,Benzinga reports. They currently have an outperform rating on the stock.

Several other equities analysts also recently issued reports on AVAH. UBS Group lifted their price target on shares of Aveanna Healthcare from $8.00 to $13.00 and gave the company a “neutral” rating in a report on Friday, August 14th. Truist Financial upped their price objective on shares of Aveanna Healthcare from $9.00 to $11.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Wall Street Zen lowered shares of Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 15th. Barclays lifted their target price on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Finally, Stephens raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $10.00 to $11.00 in a report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.89.

Aveanna Healthcare Stock Performance

Aveanna Healthcare stock opened at $13.62 on Monday. The company has a debt-to-equity ratio of 4.47, a current ratio of 1.16 and a quick ratio of 1.16. The stock has a fifty day moving average price of $9.95 and a two-hundred day moving average price of $8.03. Aveanna Healthcare has a 52-week low of $5.93 and a 52-week high of $13.98. The firm has a market capitalization of $2.97 billion, a P/E ratio of 11.07, a P/E/G ratio of 0.85 and a beta of 1.90.

Aveanna Healthcare (NASDAQ:AVAH) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.05. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%.The company had revenue of $670.48 million during the quarter, compared to analysts’ expectations of $638.61 million. As a group, analysts anticipate that Aveanna Healthcare will post 0.75 EPS for the current fiscal year.

Insider Buying and Selling at Aveanna Healthcare

In other news, major shareholder J.H. Whitney Equity Partners V sold 12,496,077 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $11.50, for a total transaction of $143,704,885.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Paul R. Vigano sold 14,500,002 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $11.50, for a total value of $166,750,023.00. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 79,746,745 shares of company stock worth $773,117,091. Insiders own 5.30% of the company’s stock.

Institutional Trading of Aveanna Healthcare

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in shares of Aveanna Healthcare by 21.2% in the 1st quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock valued at $142,000 after purchasing an additional 4,602 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Aveanna Healthcare by 8.3% during the first quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock worth $1,842,000 after buying an additional 25,974 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Aveanna Healthcare by 522.0% during the first quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock worth $407,000 after buying an additional 63,010 shares during the last quarter. Creative Planning lifted its holdings in Aveanna Healthcare by 15.1% in the second quarter. Creative Planning now owns 47,025 shares of the company’s stock valued at $246,000 after buying an additional 6,171 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Aveanna Healthcare by 65.0% in the second quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock valued at $828,000 after buying an additional 62,348 shares during the period. 87.96% of the stock is owned by institutional investors.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.